; and (II) shall document the rationale for why a covered part D drug meets the definition of a limited access drug under clause (v), if such plan restricts or limits access to a limited access drug to a subset of network pharmacies. (ii) Annual submission of information to the secretary on limited access drugs For each plan year (beginning with plan year 2026), each PDP sponsor offering a prescription drug plan shall submit to the Secretary, at a time and in a manner specified by the Secretary, with respect to each prescription drug plan offered by the sponsor during such plan year— (I) a list of all covered part D drugs that the PDP sponsor designated as a limited access drug; (II) for each covered part D drug included in the list described in subclause (I), a written rationale for why such drug meets the definition of a limited access drug; (III) a summary of the requirements imposed on network pharmacies (including all accreditation requirements, if any) to ensure appropriate handling and dispensing of each covered part D drug included in the list described in subclause (I); (IV) the percentages of each covered part D drug included in the list described in subclause (I) that is dispensed through retail pharmacies, specialty pharmacies, mail order pharmacies, or other dispensing channels as defined by the PDP sponsor, respectively; (V) the annual percentage of each covered part D drug included in the list described in subclause (I) that is dispensed through a pharmacy that is affiliated with the plan or is an affiliate (as defined in section 1860D–12(h)(4)(A)) of a pharmacy benefit manager acting on behalf of such sponsor or such plan